170787-99-2
170787-99-2
Chemical Structure
Efaproxiral sodium
Synonym(s): RSR13 sodium
- CAS No.: 170787-99-2
- Formula:C20H22NNaO4
- Molecular Weight:363.38
IUPAC Name: sodium 2-(4-(2-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-methylpropanoate
InChIKey: SWDPIHPGORBMFR-UHFFFAOYSA-M
SMILES: CC(C)(OC1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1)C(O[Na])=O
Biological Activity: Efaproxiral (RSR13) sodium is a haemoglobin (Hb) synthetic allosteric modifier. Efaproxiral sodium decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy [1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Efaproxiral sodium | 99.72% | Efaproxiral (RSR13) sodium is a haemoglobin (Hb) synthetic allosteric modifier. Efaproxiral sodium decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Efaproxiral sodium (Standard) | ≥98% | Efaproxiral (RSR13) sodium (Standard) is the analytical standard of Efaproxiral sodium (HY-13619A). This product is intended for research and analytical applications. Efaproxiral sodium is a haemoglobin (Hb) synthetic allosteric modifier. Efaproxiral sodium decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94(12):1777-1784. [Content Brief]
- [2]. Abraham DJ, et al. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry. 1992 Sep 29;31(38):9141-9. [Content Brief]
- [3]. Hou H, et al. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res. 2007 Aug;168(2):218-25. [Content Brief]
- [4]. Hou H, et al. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9. [Content Brief]
